Effect of glucagon‐like peptide‐1 receptor agonists on cardiovascular events in overweight or obese adults without diabetes: A meta‐analysis of placebo‐controlled randomized trials
Open accessAbstract
Our aim was to study the effect of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) on the risk of any cardiovascular event in adults with overweight or obesity and without diabetes. We conducted a random‐effects meta‐analysis of placebo‐controlled randomized controlled trials. Nine trials were eligible and, in total, 11 430 patients were included, of which 7702 (67%) were submitted to treatment with GLP‐1 RA. During follow‐up, 673 participants receiving GLP‐1 RA treatment (8.7%) and 416 participants receiving placebo (11.2%) had a cardiovascular event. Treatment with GLP‐1 RA versus placebo resulted in a reduction in the risk of any cardiovascular event (RR = 0.81, CI 0.70‐0.92; p = .001). In overweight or obese adults without diabetes, treatment with GLP‐1 RA reduced the risk of cardiovascular events. Our findings support the use of GLP‐1 RA for reducing the cardiovascular risk of these patients.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Both GLP-1 receptor agonists have been shown in a meta-analysis to decrease risk of CVD events in adults with overweight or obesity without diabetes (at follow-up of 32-160 weeks, 8.7% of participants receiving GLP-1 receptor agonists and 11.2% receiving placebo had an event).
“Both GLP-1 receptor agonists have been shown in a meta-analysis to decrease risk of CVD events in adults with overweight or obesity without diabetes (at follow-up of 32-160 weeks, 8.7% of participants receiving GLP-1 receptor agonists and 11.2% receiving placebo had an event).82”
From Obesity Management in Adults (2023) · cites this paper as [82]
Cites
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283 · see citing works
RoB 2: a revised tool for assessing risk of bias in randomised trials
Sterne, J. A. C., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., Cates, C. J., Cheng, H.-Y., Corbett, M. S., Eldridge, S. M., et al. (2019) · BMJ · doi:10.1136/bmj.l4898 · Cited by 33,583 · see citing works
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · see citing works
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724 · see citing works
Kristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30249-9 · Cited by 1,663 · see citing works
Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444 · see citing works
Wadden, T. A., Bailey, T. S., Billings, L. K., Davies, M., Frias, J. P., Koroleva, A., Lingvay, I., O’Neil, P. M., Rubino, D. M., Skovgaard, D., et al. (2021) · JAMA · doi:10.1001/jama.2021.1831 · Cited by 1,114 · cited 3× · see citing works
“After full-text analysis, 30 articles were further excluded, leading to the final inclusion of nine studies (Supplementary Appendix, Figure S1).1,5-12 The baseline characteristics of the participants from the eligible RCTs are shown in Table 1.”
BackgroundResultRubino, D. M., Greenway, F. L., Khalid, U., O’Neil, P. M., Rosenstock, J., Sørrig, R., Wadden, T. A., Wizert, A., Garvey, W. T., STEP 8 Investigators, et al. (2022) · JAMA · doi:10.1001/jama.2021.23619 · Cited by 995 · see citing works
le Roux, C. W., Astrup, A., Fujioka, K., Greenway, F., Lau, D. C. W., Van Gaal, L., Ortiz, R. V., Wilding, J. P. H., Skjøth, T. V., Manning, L. S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30069-7 · Cited by 850 · see citing works
on behalf of the NN8022-1923 Investigators, Wadden, T. A., Hollander, P., Klein, S., Niswender, K., Woo, V, Hale, P. M., & Aronne, L. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.120 · Cited by 842 · see citing works
O'Neil, P. M., Birkenfeld, A. L., McGowan, B., Mosenzon, O., Pedersen, S. D., Wharton, S., Carson, C. G., Jepsen, C. H., Kabisch, M., & Wilding, J. P. H. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31773-2 · Cited by 814 · see citing works
on behalf of the SCALE study group, Blackman, A., Foster, G. D., Zammit, G., Rosenberg, R., Aronne, L., Wadden, T., Claudius, B., Jensen, C. B., & Mignot, E. (2016) · International Journal of Obesity · doi:10.1038/ijo.2016.52 · Cited by 583 · see citing works
Nauck, M. A., Meier, J. J., Cavender, M. A., Abd El Aziz, M., & Drucker, D. J. (2017) · Circulation · doi:10.1161/circulationaha.117.028136 · Cited by 582 · see citing works
Davies, M. J., Aronne, L. J., Caterson, I. D., Thomsen, A. B., Jacobsen, P. B., Marso, S. P., & groups, O. B. O. T. S. A. C. A. –. L. E. I. I. W. A. W. D. (. S. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13125 · Cited by 115 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Martin, S. S., Aday, A. W., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Barone Gibbs, B., Beaton, A. Z., Boehme, A. K., et al. (2024) · Circulation · doi:10.1161/cir.0000000000001209 · Cited by 2,800 · see citing works
Martin, S. S., Aday, A. W., Allen, N. B., Almarzooq, Z., Anderson, C. A. M., Arora, P. K., Avery, C. L., Baker-Smith, C. M., Bansal, N., Beaton, A., et al. (2025) · Circulation · doi:10.1161/cir.0000000000001303 · Cited by 1,206 · see citing works
Elmaleh-Sachs, A., Schwartz, J. L., Bramante, C. T., Nicklas, J. M., Gudzune, K. A., & Jay, M. (2023) · JAMA · doi:10.1001/jama.2023.19897 · Cited by 748 · see citing works
Palaniappan, L. P., Allen, N. B., Almarzooq, Z., Anderson, C. A. M., Arora, P. K., Avery, C. L., Baker-Smith, C. M., Bansal, N., Currie, M. E., Earlie, R. S., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001412 · Cited by 312 · see citing works
Michos, E. D., López-Jiménez, F. A., & Gulati, M. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.029282 · Cited by 93 · see citing works
Neves, J. S., Vasques‐Nóvoa, F., Borges‐Canha, M., Leite, A. R., Sharma, A., Carvalho, D. M., Packer, M., Zannad, F. M., Leite-Moreira, A. F., & Ferreira, J. P. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14862 · Cited by 79 · see citing works
Self-citationGlycaemic control is still central in the hierarchy of priorities in type 2 diabetes management
Khunti, K., Zaccardi, F., Amod, A., Aroda, V., Aschner, P., Colagiuri, S., Mohan, V., & Chan, J. C. (2024) · Diabetologia · doi:10.1007/s00125-024-06254-w · Cited by 71 · see citing works
Glucagon-Like Peptide-1 Receptor Agonists Across the Spectrum of Heart Failure
Ferreira, J. P., Sharma, A., Butler, J., Packer, M., Zannad, F. M., Vasques‐Nóvoa, F., Leite-Moreira, A. F., & Neves, J. S. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad398 · Cited by 55 · see citing works
Self-citationSingh, S. T., Garg, A., Tantry, U. S., Bliden, K. P., Gurbel, P. A., & Gulati, M. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102403 · Cited by 32 · see citing works
Yin, Y., Zhang, M., Cao, Q., Lin, L., Lu, J., Bi, Y., & Chen, Y. (2025) · Journal of Diabetes · doi:10.1111/1753-0407.70082 · Cited by 31 · see citing works
Tang, A. S. P., Hsu, J. T. Y., Chong, S. K. S., Quek, J., Shek, G., Sulaimi, F., Chan, K. E., Anand, V. V., Chong, B., Mehta, A., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02840-3 · Cited by 26 · see citing works
Leveraging metabolism for better outcomes in heart failure
Ng, Y. H., Koay, Y. C., Marques, F. Z., Kaye, D. M., & O’Sullivan, J. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae216 · Cited by 16 · see citing works
The Impact of Glucagon-Like Peptide-1 Receptor Agonists on Kidney Outcomes
Mendonça, L., Moura, H., Castro‐Chaves, P., Neves, J. S., & Ferreira, J. P. (2024) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000584 · Cited by 16 · see citing works
Self-citationMaan, M. S. A., Sohail, A. H., Sulaiman, S. A., Mansoor, L., Cohen, E. M., Adekolu, A. A., Abunnaja, S., Szoka, N. L., Tabone, L. E., Thakkar, S. J., et al. (2025) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2025.116242 · Cited by 13 · see citing works
Zomer, E., Zhou, J., Nelson, A. J., Sumithran, P., Nanayakkara, S., Ball, J., Kaye, D. M., Liew, D., Nicholls, S. J., Stub, D. A., et al. (2024) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcae063 · Cited by 12 · see citing works
Treatment and Monitoring of Idiopathic Intracranial Hypertension
Chen, J. J.-W., & Mollan, S. P. (2025) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/cont.0000000000001586 · Cited by 10 · see citing works
Kelkar, R., Barve, N., Kelkar, R., Kharel, S., Khanapurkar, S., & Yadav, R. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1453297 · Cited by 9 · see citing works
Role of hypothalamus function in metabolic diseases and its potential mechanisms
Zhang, X., Yang, J., Li, Y., Li, Y., & Li, G. (2025) · PeerJ · doi:10.7717/peerj.19532 · Cited by 7 · see citing works
The weight reduction mediated by anti-obesity medication and the cardiovascular outcome
Guo, Y., Chu, L., Cai, X., Wu, H., Yan, J., Li, Z., Jiao, R., Bai, S., Yang, W., Lv, F., et al. (2024) · iScience · doi:10.1016/j.isci.2024.110867 · Cited by 6 · see citing works
Impact of medical versus surgical weight loss on cardiovascular outcomes
Ostapenko, A., & Ahmed, B. H. (2025) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2025.03.004 · Cited by 4 · see citing works
Overweight and obesity in metabolic syndrome
Nedogoda, S. V., & Васильевна, Ц. О. (2025) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2025-6535 · Cited by 4 · see citing works
Voetmann, L. M., Rolin, B., Kirk, R. K., Knudsen, L. B., Merkestein, M., Ahnfelt‐Rønne, J., Kodal, A. L. B., Jessen, C., Ozen, A. I., Pyke, C., et al. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70510 · Cited by 2 · see citing works
New perspectives on semaglutide in cardiovascular disease
Seferovic, P. M., & Polovina, M. M. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01734-9 · Cited by 2 · see citing works
Fussing, F. H., Davodian, L. W., Davodian, D. W., Johansen, N. D., Kumarathurai, P., Modin, D., Sattler, S. M., Larroudé, C. E., Risum, N., Vinther, M., et al. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag114 · Cited by 2 · see citing works
Tekengne, B. O. T., Eke, C. I., Cumaaran, C., Ozigbo, A. A., Okoyeuzu, C., Okhagbuzo, I. M., Sadiq-Onilenla, R. A., & Okobi, O. E. (2025) · Cureus · doi:10.7759/cureus.91722 · Cited by 1 · see citing works
Paceana, M.-A., Mititelu-Tarțău, L., Boboc, I. K. Ş., Oancea, C. N., Berbecaru-Iovan, A., Foia, C. I., Tartau, C. G., & Bogdán, M. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18050620 · Cited by 1 · see citing works
Gillikin, A. P., Lee, Y., Varney, C., Dang, J. T., Tsung, A., Nimeri, A. A., & Shin, T. H. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.104033 · Cited by 1 · see citing works
Methodological issues with meta‐analysis
Ryan, D. H. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14742 · Cited by 1 · see citing works
Letter of reply to the letter by Ryan
Ferreira, J. P., Leite, A. R., Gonçalves, A., Borges‐Canha, M., & Neves, J. S. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14743
Self-citationNew obesity drug therapies – what is the added value?
Keller, U. B. (2022) · doi:10.36000/hbt.2022.07.002
Bancks, M. P. (2023) · Diabetes Care · doi:10.2337/dci23-0023
He, Y., Cui, L., Wang, X., Wang, X., Liu, S., Bai, C., Zhen, J., Liu, T., & Gu, X. (2025) · Research Square · doi:10.21203/rs.3.rs-6307329/v1
Ferreira, J. P., Marques, P. S., Haring, B., & Neves, J. S. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.70055
Self-citationDisu, F., Okoro, N. L., Mochu, A. W., Martey, A. R., Shittu, S. A., Green, J. T., & Azubike, W. C. (2025) · Cureus · doi:10.7759/cureus.94373
Zhang, Y., Zhao, Z., Higgins, V., & Barlow, S. G. (2026) · Current Medical Research and Opinion · doi:10.1080/03007995.2026.2689307
Yalçın, N. (2026) · Cukurova Anestezi ve Cerrahi Bilimler Dergisi · doi:10.36516/jocass.1933450
Weng, C., Cherukuru, R., Chou, C.-C., Lin, J., Lin, C., Chan, P. A., & Bennett, C. L. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113454
Rashid, M., Lee, E. L., Veettil, S. K., Dhippayom, T., Cheng, A. Y. Y., SIMONETTI, J. S., & Chaiyakunapruk, N. (2026) · Obesity Reviews · doi:10.1111/obr.70198
- Authors
- Leite, A. R., Angélico‐Gonçalves, A., Vasques‐Nóvoa, F., Borges‐Canha, M., Leite‐Moreira, A., Neves, J. S., & Ferreira, J. P.
- Affiliations
- Universidade do Porto (PT)
- Cardiovascular R&D Center, Faculty of Medicine University of Porto Porto Portugal
- Inserm (FR)
- Corresponding author
- Angélico‐Gonçalves, António
- ORCID
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2022-05-03
- Volume
- 24
- Issue
- 8
- Pages
- 1676-1680
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W4225989725
- Cited by
- 39
- References
- 14
- Citations by year
- 2026: 8 · 2025: 14 · 2024: 9 · 2023: 4 · 2022: 4
- FWCI
- 5.75
- Type
- journal article
- Language
- en
- Open access
- green
- hal.univ-lorraine.fr
- Licence
- Locations
- Diabetes Obesity and Metabolism (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- GLP-1 receptor agonists, cardiovascular events, obesity, overweight, non-diabetic adults, cardiovascular risk reduction
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Adult, Cardiovascular Diseases, Diabetes Mellitus, Humans, Obesity, Randomized Controlled Trials as Topic, Overweight, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
